1 / 98

MANAGEMENT OF ATRIAL FIBRILLATION

MANAGEMENT OF ATRIAL FIBRILLATION. VINOD G V. Definitions. Paroxysmal AF - self-terminating, usually within 48 h, may continue for up to 7 days. Persistent AF - when an AF episode either lasts longer than 7 days or requires termination by cardioversion .

nevaeh
Download Presentation

MANAGEMENT OF ATRIAL FIBRILLATION

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MANAGEMENT OF ATRIAL FIBRILLATION VINOD G V

  2. Definitions • Paroxysmal AF - self-terminating, usually within 48 h, may continue for up to 7 days. • Persistent AF - when an AF episode either lasts longer than 7 days or requires termination by cardioversion. Long-standing persistent AF has lasted for ≥1 year when it is decided to adopt a rhythm control strategy. Permanent AF-DC version failed or not attempted • Recurrent AF-has had 2 or more episodes

  3. “lone AF” • generally applies to young individuals under 60 y of age without clinical or echocardiographic evidence of cardiopulmonary disease including hypertension . • have a favorable prognosis with respect to thromboembolism and mortality.

  4. Haemodynamics • Loss of atrial contraction • A rapid ventricular rate • An irregular ventricular rhythm • Loss of mechanical AV synchrony affects ventricular filling esp. when left ventricle has reduced compliance.

  5. 3 objectives Rate control prevention of thromboembolism correction of the rhythm disturbance,

  6. Type and duration of AF • Severity and type of symptoms • Associated cardiovascular disease • Patient Age • Associated medical conditions • Pharmacological and nonpharmacological therapeutic • options.

  7. Rapid ventricular rate produce symptoms Tachycardia related cardiomyopathy

  8. Rate control • Strict rate control: Resting HR -60-80 Moderate exercise 90-110 • Lenient HR Resting HR <100 RACE II (RAte Control Efficacy in permanent atrial fibrillation) trial did not identify a benefit of stringent rate control over lenient rate control therapy in 614 patients

  9. Primary Outcomes Cardiac death CHF Stroke Systemic embolism Major bleed Syncope Sust VT Cardiac arrest Life threat compl of antiarrhythmic Pacemaker Secondary Outcomes Symptoms

  10. Beta-Blockers useful in the presence of high adrenergic tone or symptomatic myocardial ischaemia • Non dihydropyridine CCB-Diltiazem,verapamil • Digoxin-effective at rest ,not during exercise

  11. Rhythm control

  12. Theoretical Benefit of Rhythm Control • Improved hemodynamics • Relief of symptoms • Improved exercise tolerance • Reduced risk of stroke • Avoidance of anticoagulants

  13. Rhythm control • Pharmacological • Non pharmacological Cardioversion Catheter Ablation

  14. Cardioversion in AF • Pharmacological • Electrical cardioversion

  15. DC Cardioversion • Delivery of an electric shock synchronised with the intrinsic activity of heart by sensing the R wave • Successful cardioversion depends on Duration of AF Current density delivered to atrial myocardium

  16. Joglar JA et al Am J Cardio 2000

  17. Mittal S et al Ciculation 2000

  18. Elhendy A et al Am J Cardio 2002

  19. Pharmacological cardioversion • Simple • Less efficaious • More effective in AF <7 day duration • Problems of drug toxicity

  20. AF lasting <1 wk – cardioversion -using oral flecainide, propafenone, dofetilide, and intravenous ibutilide. • For longer duration- iv dofetilide( also amiodarone and ibutilide may be useful) • Single oral dose of propafenone or flecainide – in recent onset AF (pill in the pocket)

  21. 2 strategies • Oral warfarin with a therapeutic INR (2–3) for 3 to 4 weeks before cardioversion followed by continued warfarin thereafter • Transesophageal echocardiography (TEE) and heparin immediately before cardioversion followed by oral warfarin thereafter. • Left atria – stunning effect. So anticoagulation is to be continued for 4 wks

  22. AF upto 7 days

  23. AF >7 days

  24. Pharmacological Rhytm control

  25. Major Trials Comparing Rhythm Strategy and Rate Strategy Major trials include: • AFFIRM (Atrial Fibrillation Follow-Up Investigation of Rhythm Management ) • RACE (rate control versus electrical cardioversion) • PIAF (pharmacological intervention in AF) • AF-CHF Major overall findings: • Rhythm-control strategy was not superior to rate-control strategy in terms of morbidity/mortality • Appropriate choice of therapy should be based on each patient’s symptoms and disease • rate control, prevention of thromboembolism, and correction of the rhythm disturbance - these strategies are not mutually exclusive

  26. AFFIRM : 5 Year Outcomes NO DIFFERENCE:Death, major bleed ,disabling stroke,cardiac arrest Sinus rhythm maintained in only 63% of rhythm control group

  27. AFFIRM Trial • No survival advantage to rhythm control. • Rhythm control patients were more likely to be hospitilized with adverse drug effects. • Both groups had similar stroke risk (1% per yr) • Majority of strokes when warfarin stopped or INR subtherapeutic • Warfarin required long term even if sinus rhythm restored • Torsades, bradycardic arrest more common with rhythm control.

  28. Attempts at restoration of sinus rhythm not always successful • AFFIRM Trial: only 63% of “rhythm control” group were in sinus rhythm • Antiarrhythmics used to maintain sinus rhythm associated with a 25-50% annual failure rate. • Long term anticoagulation not mandated in the “rhythm control” group • Those in afib at risk for stroke • Medications used to maintain sinus rhythm risk of proarrhythmia and other toxicity

  29. Vernakalant • Acts preferentially in atria • Blocking several ion channels • Prolongation of atrial refractoriness • Rate dependent slowing of atrial conduction • Little impact on ventricular repolarization Pharmacological cardioversion of AF <7 days or <3days for patients after cardiac surgery

  30. AVRO Double-blind,active-controlLed -i.v. amiodarone N=232 Vernakalantn = 116, Amiodaronen = 116 Hypertension(71.6%) ischaemic heart disease(22.4%) myocardial infarction (8.2%) heartfailure(19.8%)(NYHA I- 45.7%, NYHA54.3%) valvular heart disease, 6.9% AF 3–48 h (median 17.7 h) Time to conversion 11m Conversion to SR- 51.7% vs. 5.2% P <0.0001 Reduction in symptoms at 2 h reported by 53.4% patients in the vernakalantgroupvs. 32.8% in the Amiodarone group P = 0.0012

  31. “Pill in the Pocket” strategy • Preferred in • Paroxysmal AF with no structural heart disease • Self administration of a single oral dose of drug shortly after the start of palpitations • Decrease hospital visits Propafenone 450-600mg Flecainide 200-300mg

  32. Anti-arrhythmic drugs for maintaining sinus rhythm

  33. Selection of specific agent depends on underlying cardiac disease

  34. CATHETER ABLATION IN AF

  35. Factors • Factors that trigger • Factors that perpetuate • Triggering foci of rapidly firing cells within the sleeve of atrialmyocytes extending into the pulmonary veins - shown to be the underlying mechanism of most paroxysmal AF

More Related